Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by
progressive cognitive decline and the accumulation of beta-amyloid plaques and tau tangles …

Alzheimer's disease (AD) is the most common form of dementia affecting specifically older
population. AD is an irreversible neurodegenerative CNS disorder associated with complex …

Alzheimer's disease (AD), as a neurodegenerative disorder, usually develops slowly but
gradually worsens. It accounts for approximately 70% of dementia cases worldwide, and is …

Sigma (σ) receptors are a class of unique proteins with two subtypes: the sigma-1 (σ1)
receptor which is situated at the mitochondria-associated endoplasmic reticulum (ER) …

Alzheimer's disease (AD) is the most prevalent neurodegenerative disease, representing
80% of the total dementia cases. The “amyloid cascade hypothesis” stablishes that the …

Alzheimer's disease (AD) remains the foremost cause of dementia and represents a
significant unmet healthcare need globally. The complex pathogenesis of AD, characterized …

Benzimidazole and benzoxazole derivatives are included in the category of medical drugs in
a wide range of areas such as anticancer, anticoagulant, antihypertensive, anti …

With the goal of combating the multi-faceted Alzheimer's disease (AD), a series of
Rivastigmine-Benzimidazole (RIV–BIM) hybrids was recently reported by us as multitarget …

Rivastigmine is an acetylcholinesterase (AchE) and butyrylcholinesterase (BchE) inhibitor
drug approved by the US Food and Drug Administration (FDA) for the treatment of mild to …

Butyrylcholinesterase (BChE), also known as pseudocholinesterase and serum
cholinesterase, is an isoenzyme of acetylcholinesterase (AChE). It mediates the degradation …